Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
Healthy subjects will take study drug by mouth twice a day for 7 consecutive days, blood and
cervicovaginal samples will be taken most mornings around the AM dose. Two visits, ~14 hrs in
length will be required on Day 1 and 7. The purpose of this study is to measure how much
raltegravir is found in the genital tract after taking it orally.